Table 1. Overview of all patients undergoing intraductal RFA followed by locoregional tumor treatments for stent-occlusion and malignant biliary obstruction.
| Patient | Sex/age | Tumor(staging) | No. of RFA | Length of the obstruction (cm) | No. of locoregional tumor treatments | Follow-up (days) | Outcome |
|---|---|---|---|---|---|---|---|
| 1 | M/73 | Distal CCA*(T3N1M0) | 2 | 5.2 | 3 | 523 | Alive |
| 2 | F/50 | Distal CCA(T2N1M0) | 2 | 4.7 | 3 | 534 | Alive |
| 3 | F/73 | Distal CCA(T2N1M0) | 1 | 3.8 | 3 | 511 | Alive |
| 4 | M/65 | Distal CCA(T2N1M0) | 1 | 4.4 | 3 | 478 | Dead |
| 5 | M/53 | DistalCCA(T2N1M0) | 1 | 4.9 | 2 | 484 | Dead |
| 6 | M /46 | CCA Bismuth I*(T3N0M0) | 1 | 5.3 | 4 | 442 | Alive |
| 7 | M /56 | CCA Bismuth IV*(T3N1M0) | 1 | 4.2 | 3 | 234 | Alive |
| 8 | M /64 | HCC(T3N1M0) | 1 | 3.8 | 3 | 187 | Dead |
| 9 | F/57 | HCC(T3N1M0) | 1 | 3.7 | 3 | 422 | Dead |
| 10 | F/72 | HCC(T3N0M0) | 1 | 4 | 3 | 334 | Dead |
| 11 | M/61 | HCC(T3N0M0) | 1 | 3.5 | 4 | 544 | Alive |
| 12 | M /52 | Gallbladder adenocarcinoma*(T3N1M0) | 1 | 5.1 | 2 | 218 | Dead |
| 13 | M /58 | Gallbladder adenocarcinoma*(T3N0M0) | 1 | 4.9 | 2 | 278 | Dead |
| 14 | M /51 | Gallbladder adenocarcinoma*(T3N0M0) | 1 | 4.2 | 2 | 308 | Dead |
The number of follow-up months denotes the months from the first RFA in each patient.
Locoregional tumor treatments included TACE or superselective intra-arterial chemotherapy and embolization of tumor-feeding arteries.
*: These patients had liver metastases. F: Female; M: male; CCA: cholangiocarcinoma; HCC: hepatocellular carcinoma; RFA: intraductal radiofrequency ablation.